How small molecule biomarkers can help decipher autoimmune disease dynamics and inform drug development strategies.
See how Sapient enables focused biomarker discovery analyses with rapid time-to-insight.
These ready-to-order panels speed time-to-insight through targeted exploration of known molecules.
A discussion at the intersection of high throughput biomarker profiling, advanced data analytics, and biological insight.
Now available on demand! Explore how small molecule biomarkers can drive greater understanding of autoimmune diseases.
Explore how dynamic biomarkers of target engagement and PD can help decipher the heterogeneity of ADCs and their targets.
This case study details the discovery of a biomarker of biological processes in patients with sequence-verified mitochondrial disease.
Now available on demand! Explore the applications for small molecule biomarkers in cell & gene therapy development.
“Out of graduate school, Dr. Mohit Jain (co-founder and CEO of Sapient, but a university professor at the time) approached…
At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. Biomarkers allow us…
“I would argue that for nearly every common disease, there are multiple forms of the disease that have been amalgamated…
The inherent heterogeneity in patient populations can often lead to variable drug response. We recently worked with a client who…
Did you know that underlying risks for most common human diseases are not encoded in DNA sequence? Rather, they are…
There are tens of thousands of unmapped molecules circulating in human blood – thousands of which could represent robust biomarkers.…
August 2, 2023—San Diego, CA—Sapient, a biomarker discovery organization providing bespoke services for metabolomics and lipidomics data generation and analysis,…
The PD-1 pathway has transformed the development of immunotherapies as a means to reawaken the immune system to target cancer…
Watch the Livestream Recording | Presented by Bruker Watch the full recording of our recent lab tour showing how Sapient’s next-generation, ultra-high…
Now On Demand | Hosted by Nature Research Watch Now Human disease is a highly dynamic process. While next-generation genomic sequencing has…
The incidence and prevalence of nonalcoholic fatty liver disease (NAFLD) continue to rise worldwide, estimated to affect over one-quarter of…
“Diagnostics have evolved tremendously. You could argue that the greatest benefit in human survival has come over the last 50…
Preclinical safety assessments play a pivotal role in mitigating risk to enhance drug development success. Early identification of toxicological effects…
“My hope is that in the very near future, in the next decade, an individual would go to a doctor’s…
Biocom California recently asked Sapient to contribute an article for its Lifelines Magazine, a forum sharing insights and innovations that are leading…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Adaptive clinical trial designs are an emerging approach that bring flexibility to traditional linear study designs by adding a “review,…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Greater discovery is enabled when data from individual disease and cohort studies can be homogenized and linked together, revealing biological…
Now On Demand | Hosted by AAPS Small molecule biomarkers represent dynamic indicators of adverse effects in the setting of drug exposure…
Now On Demand | Hosted by Oxford Global Advances in mass spectrometry resolution and sensitivity have enabled increasingly comprehensive views into the…
There is increasing evidence of the human gut microbiome’s link to health and disease. Exploring the composition and function of…
If you look at the data, the best drugs work in only 50% of people. Sapient’s Founder and CEO, Dr. Mo…
Adaptive clinical trial designs seek to add flexibility to the fixed, linear “design-conduct-analyze” sequence of conventional clinic trials. Instead of assessing…
Technology Networks’ Anna MacDonald sat down with Sapient’s Dr. Mo Jain for this Industry Insights piece to discuss the importance of improving biomarker…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Biocompare recently spoke to a panel of experts, including Sapient’s CEO and Founder, Dr. Mo Jain, to get their takes…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Now On Demand | Hosted by AAPS Will a patient respond or not respond to the given therapy? That is the fundamental…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Understanding the risk factors that give rise to human disease is essential to early detection and development of effective treatments…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
There are tens of thousands of unknown molecules circulating in human blood – thousands of which could represent robust biomarkers.…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
CNS diseases can have a wide range of symptoms which can make them difficult to diagnose and treat based on…
Having a multidisciplinary team gives us deep & diverse expertise to tap across our discovery endeavors. This series shares those…
Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human lipidome at a rate that is unmatched…
Now On Demand | Hosted by Fierce Pharma Watch Now In this session, Sapient discusses application of its next-generation mass…
Disease processes are complex. Individuals with the same genetic disorder, symptoms, and/or diagnosis can have varied prognosis and response to…
Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling Now On Demand | Presented by Technology…
Dr. Jain also shares his background and what led to him to creating Sapient along with the company’s own next-generation…
Now On Demand | Hosted by AAPS Watch Now While next-generation sequencing has been instrumental in advancing genomics-based precision medicine,…
Sapient recently contributed a piece to Fierce Pharma discussing the new biological and disease insights that small molecule biomarkers can…
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes…
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital…
Now On Demand | Hosted by AAPS Watch Now Genome-wide association studies (GWAS) have been transformative in elucidating the genetic…
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention,…
An individual’s phenotype is not dictated solely by their genetic variants. Environmental factors – where we live, what we eat,…
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and…
Untargeted biomarker discovery aims to uncover previously unknown factors that associate with biologically relevant changes in human health and disease,…
Now On Demand | Hosted by AAPS Watch Now A key aspect of the drug discovery pipeline is evaluation of in…
Retrospective analyses conducted by major pharmaceutical companies on their drug pipelines have revealed that close to one-fifth of Phase II failures due…
A drug candidate with an associated biomarker is 2−10x more likely to obtain FDA approval. Why? Because biomarkers help to…
Now On Demand | Hosted by AAPS Watch Now Diseases are singularly defined but often represent varied groupings of contributing factors…
The composition and function of the human gut microbiome are linked to health and disease. Increasing evidence of gut microbes’…
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for…
High throughput technologies can now capture and measure a huge number of biological molecules within a single human cell or…
Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While…
Sapient leverages its next-generation mass spectrometry approaches to probe deeper into the human metabolome at a rate is unmatched for…
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area…
At Sapient, we believe biomarker-driven drug development can transform lives – and accelerate the process at a fraction of the…
Why are large, expensive clinical trials so common? It stems from the challenge of needing to demonstrate treatment efficacy in…
Now On Demand | Hosted by AAPS Circulating biomarker discovery is a critical component of the drug discovery process, identifying markers…
The omics revolution has enabled many breakthroughs in our understanding of disease biology, but the productivity of clinical drug development…
Nontargeted LC-MS can assay thousands of chemical entities in a single biospecimen, but in that crush of data, how do…
10421 Wateridge Circle
Suite 100
San Diego, CA 92121
© 2023 Sapient Bioanalytics, LLC. All rights reserved.
SAPIENT, the SAPIENT Logo, ACCELERATE HUMAN DISCOVERY,
and SPECIFICITY AT SCALE are trademarks of Sapient Bioanalytics, LLC
